GlassScriptPhysician profile
Bridgett Middleton
NPI 1750032678
$3,001.27
in general payments reported to CMS, 2019-2025
33 companies · $1,845 in 2025
The $1,845 reported for 2025 was more than what 94% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $87.37 · 2023: $275 · 2024: $793 · 2025: $1,845.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,914.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,913.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $478.32 | 2022-2025 | |
| Corcept Therapeutics | $313.23 | 2025 | Korlym |
| Novo Nordisk INC | $238.37 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Exact Sciences Corporation | $229.50 | 2023-2024 | Cologuard Collection Kit |
| Lilly USA, LLC | $193.10 | 2023-2025 | Jardiance, Mounjaro, Kisunla |
| Pfizer INC. | $183.84 | 2024-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.00 | 2024-2025 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals LP | $116.24 | 2022-2025 | Farxiga, Airsupra |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $111.25 | 2024-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $102.11 | 2024-2025 | Rexulti |
| Amgen INC. | $91.59 | 2024 | Otezla, Repatha, Prolia |
| Axsome Therapeutics, INC. | $85.02 | 2025 | Symbravo, Auvelity |
| Bayer Healthcare Pharmaceuticals INC. | $77.81 | 2022-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.71 | 2024-2025 | Jardiance, Synjardy, Tradjenta |
| Merck Sharp & Dohme LLC | $59.70 | 2024-2025 | Gardasil 9, Capvaxive, Gardasil |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $53.09 | 2024-2025 | Voquezna |
| Sumitomo Pharma America, INC. | $51.41 | 2024-2025 | Gemtesa |
| Astellas Pharma US INC | $44.20 | 2024-2025 | Veozah |
| Lundbeck LLC | $42.25 | 2025 | Rexulti |
| Azurity Pharmaceuticals, INC. | $40.00 | 2025 | Edarbi, Azmiro |
| Sanofi-Aventis U.S. LLC | $34.84 | 2024-2025 | |
| Glaxosmithkline, LLC. | $34.42 | 2025 | Trelegy Ellipta |
| Harmony Biosciences LLC | $29.38 | 2025 | |
| Verrica Pharmaceuticals INC. | $24.36 | 2024 | Ycanth |
| Boston Scientific Corporation | $24.28 | 2025 | Wavewriter Alpha Prime 16 |
| Antares Pharma, INC. | $21.98 | 2025 | Xyosted |
| Vanda Pharmaceuticals INC. | $21.47 | 2024 | Fanapt, Hetlioz |
| Shield Therapeutics INC | $20.93 | 2025 | |
| Hologic Sales and Service, LLC | $18.64 | 2024 | Aptima |
| Ardelyx, INC. | $17.49 | 2025 | Ibsrela |
| Esperion Therapeutics, INC. | $16.52 | 2025 | Nexletol |
| Ibsa Pharma INC. | $15.63 | 2025 | Tirosint, Licart, Flector |
| Regeneron Healthcare Solutions, INC. | $15.59 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bridgett Middleton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.